Skip to main content
TipRanks
Go Ultimate75% OFF

Douglas Drysdale Insider Profile

4 Followers

Douglas Drysdale, former Chief Executive Officer, Director at Pernix Therapeutics, holds 95.16K shares in Pernix Therapeutics (Ticker: PTXTQ). Most recently, Douglas Drysdale Bought 8,500 shares of Pernix Therapeutics on Aug 19, 2015 for an estimated value of $39.78K.

Douglas Drysdale's Trading History

PTXTQ
Pernix Therapeutics
Aug 19, 2015―Informative Buy39.78K$2.66K
PTXTQ
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Aug 19, 2015Informative Buy$39.78K8,500$4.68-82.90%
May 06, 2015Informative Buy$102.24K16,000$6.39-91.70%
Aug 12, 2014Uninformative Sell$712.62K187,500$6.67―

You May Also Like

Douglas Drysdale insider profile FAQ

What is the percentage of profitable transactions made by Douglas Drysdale?
The percentage of profitable transactions made by Douglas Drysdale is 0%.
What is the average return per transaction made by Douglas Drysdale?
The average return per transaction made by Douglas Drysdale is -87.30%.
What stocks does Douglas Drysdale hold?
Douglas Drysdale holds: PTXTQ stocks.
What was Douglas Drysdale’s latest transaction?
Douglas Drysdale’s latest transaction was an Informative Buy of $39.78K.
What was Douglas Drysdale's most profitable transaction?
Douglas Drysdale’s most profitable transaction was an Informative Buy of PTXTQ stock on August 19, 2015. The return on the trade was -82.90%.
What is Douglas Drysdale's role in Pernix Therapeutics?
Douglas Drysdale's role in Pernix Therapeutics is Chief Executive Officer, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.